Core Viewpoint - Ligand Pharmaceuticals is celebrating significant milestones, including the ringing of The Nasdaq Opening Bell, which reflects the company's transformation into a profitable and infrastructure-light organization focused on biopharmaceuticals [2][3]. Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company that supports the clinical development of high-value medicines through financing and licensing technologies [3]. - The company's business model aims to create a diversified portfolio of revenue streams from biotech and pharmaceutical products while maintaining a low corporate cost structure [3]. - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3]. Recent Developments - The company has made significant progress over the past few years, focusing on acquiring and generating royalties from a diverse portfolio of biopharmaceutical products [2]. - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [3]. - Captisol® optimizes drug solubility and stability, while NITRICIL™ allows for tunable dosing and adjustable drug release profiles [3]. Future Commitment - Ligand is committed to building on its recent momentum and supporting partners in developing breakthrough medicines for patients, aiming to create long-term value for shareholders [2].